Abstract
Neuroblastomas are the most common solid tumours in early childhood. Currently, the prognosis of patients is evaluated almost exclusively on the basis of molecular-genetic markers from a biopsy sample of tumour tissue. This study is focused on evaluating the potential use of 3‑methoxytyramine as an alternative non-invasive prognostic marker for patients with neuroblastoma. For this purpose, a method was developed to determine free 3‑methoxytyramine in urine using liquid chromatography coupled with tandem mass spectrometric detection. The method was fully validated and subsequently tested on 25 pediatric urine samples. In the group of patients with a poor prognosis, the median value of free 3-methoxytyramine was 666.7 nmol mmol−1Krea, while in the group with a favourable prognosis, it was 168.4 nmol mmol−1Krea. The analysis of pediatric urine samples from neuroblastoma patients revealed statistically significant differences in the concentration of free 3‑methoxytyramine (P < 0,05) between the low/medium-risk group and the high-risk group.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call